{
    "clinical_study": {
        "@rank": "94173", 
        "acronym": "AK", 
        "arm_group": [
            {
                "arm_group_label": "calcipotriol plus 5-fluorouracil", 
                "arm_group_type": "Experimental", 
                "description": "calcipotriol 0.005% ointment and 5-fluorouracil 5% cream are mixed at 1:1 weight ratio. The compounded medication is applied topically twice a day for 4 days."
            }, 
            {
                "arm_group_label": "5-fluorouracil plus vaseline", 
                "arm_group_type": "Active Comparator", 
                "description": "5-fluorouracil 5% cream and vaseline are mixed at 1:1 weight ratio. The compounded medication is applied topically twice a day for 4 days."
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to determine the effectiveness of a new combination\n      therapy for actinic keratosis. This study investigates a new indication for an FDA-approved\n      topical medication, calcipotriol, for treatment of actinic keratosis, including how well it\n      works and how safe it is when used in combination with the standard of care medication\n      (5-fluorouracil) for the skin condition."
        }, 
        "brief_title": "Actinic Keratosis Study", 
        "condition": "Actinic Keratosis", 
        "condition_browse": {
            "mesh_term": [
                "Keratosis", 
                "Keratosis, Actinic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age of at least 50 years\n\n          -  Presence of four to fifteen clinically typical, visible, and discrete actinic\n             keratoses in 25 cm2 on any of the four anatomical sites: scalp, face, right upper\n             extremity and left upper extremity\n\n          -  Ability and willingness of the patient to participate in the study (Informed consent\n             is obtained)\n\n        Exclusion Criteria:\n\n          -  Treatment area is within 5 cm of an incompletely healed wound or a suspected\n             basal-cell or squamous-cell carcinoma\n\n          -  Treatment area contained hypertrophic and hyperkeratotic lesions, cutaneous horns, or\n             lesions that had not responded to repeated cryotherapy\n\n          -  Recent (within a month) use of medications that could interfere with evaluation of\n             the treatment area (e.g., topical medications, artificial tanners, immunosuppressive\n             medications, immunomodulating agents, cytotoxic drugs, ultraviolet B phototherapy,\n             other therapies for actinic keratoses, or oral retinoids)\n\n          -  Premenopausal Women (to avoid any risk of pregnancy)\n\n          -  History of hypercalcemia or clinical evidence of vitamin D toxicity"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02019355", 
            "org_study_id": "201303070"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "calcipotriol plus 5-fluorouracil", 
                    "5-fluorouracil plus vaseline"
                ], 
                "intervention_name": "5-fluorouracil 5% cream", 
                "intervention_type": "Drug", 
                "other_name": "Efudex"
            }, 
            {
                "arm_group_label": "calcipotriol plus 5-fluorouracil", 
                "intervention_name": "Calcipotriol 0.005% ointment", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Calcipotriene", 
                    "Dovonex", 
                    "MC 903"
                ]
            }, 
            {
                "arm_group_label": "5-fluorouracil plus vaseline", 
                "intervention_name": "Vaseline", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluorouracil", 
                "Petrolatum", 
                "Calcipotriene", 
                "Calcitriol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 17, 2013", 
        "location": {
            "contact": {
                "email": "mtabacch@wustl.edu", 
                "last_name": "Mary Tabacchi", 
                "phone": "314-362-8171"
            }, 
            "contact_backup": {
                "email": "sdemehri@dom.wustl.edu", 
                "last_name": "Shawn Demehri, MD,PhD"
            }, 
            "facility": {
                "address": {
                    "city": "Saint Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63310"
                }, 
                "name": "Washington University School of Medicine"
            }, 
            "investigator": {
                "last_name": "Shawn Demehri, MD, PhD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Role of Calcipotriol in Treatment of Pre-cancerous Skin Lesions", 
        "overall_official": {
            "affiliation": "Washington University School of Medicine", 
            "last_name": "Lynn Cornelius, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To compare the efficacy of topical 5-fluorouracil+calcipotriol vs. 5-fluorouracil alone in treatment of actinic keratosis in patients with multiple actinic keratoses at each of the four anatomical sites (scalp, face, right upper extremity and left upper extremity). The outcome of interest is percentage change from baseline number of actinic keratoses in the target treatment area on scalp, face, right upper extremity and left upper extremity at 8 weeks after treatment.", 
            "measure": "percentage of change in the number of actinic keratoses from baseline", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02019355"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Washington University School of Medicine", 
            "investigator_full_name": "Lynn Cornelius, MD", 
            "investigator_title": "Chief, Division of Dermatology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "o\tTo determine complete and partial (>75%) clearance of actinic keratoses at 8 weeks after treatment.", 
                "measure": "complete and partial (>75%) clearance of actinic keratoses", 
                "safety_issue": "No", 
                "time_frame": "8wks"
            }, 
            {
                "description": "To determine the composite scores  of erythema, itching and pain (determined using standardized scales) following topical application of 5-fluorouracil+calcipotriol vs. 5-fluorouracil alone at the end of the 4-day treatment period.", 
                "measure": "Composite score of erythema, itching and skin pain after topical 5-fluorouracil+calcipotriol vs. 5-fluorouracil alone treatment of actinic keratoses", 
                "safety_issue": "Yes", 
                "time_frame": "4days"
            }, 
            {
                "description": "To examine the induction of TSLP expression in keratinocytes by calcipotriol at the site of the actinic keratoses at the end of 4-day treatment of course.", 
                "measure": "Induction of TSLP expression in keratinocytes by calcipotriol", 
                "safety_issue": "No", 
                "time_frame": "4 days"
            }, 
            {
                "description": "To determine any differences in response to topical 5-fluorouracil+calcipotriol vs. 5-fluorouracil alone between the four anatomical sites at 8 weeks after treatment.", 
                "measure": "differences in response to topical 5-fluorouracil+calcipotriol vs. 5-fluorouracil alone between the four anatomical sites", 
                "safety_issue": "No", 
                "time_frame": "8wks"
            }
        ], 
        "source": "Washington University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}